Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2008

View Archived Issues

Ispinesib appears to be well tolerated in phase I/II breast cancer study

Phase I evaluation of everolimus in hepatocellular carcinoma continues

VEGF-Trap results disappointing in phase II metastatic breast cancer study

Dose-related efficacy seen with AVE-0010 in type 2 diabetes

Panobinostat's efficacy in solid and hematologic tumors opens a new line of research in SCLC

Health Canada approves Stem Cell's phase IIa study of hCG and EPO in TBI

Upstream and Makerere University initiate animal efficacy for trypanosomiasis treatment

Takeda to initiate Japanese phase III trial of cetilistat and pay milestone payment to Alizyme

Bayer HealthCare acquires Direvo for EUR 210 million cash

Javelin completes enrollment in phase III clinical study of Dyloject in postoperative pain

Generex reaches enrollment milestone in phase III clinical trial of Oral-lyn

Y's Therapeutics completes phase IIa clinical trial of YSPSL for IRI in kidney transplants

Pluristem reports final results from preclinical animal efficacy studies of PLX-PAD

Ambrilia develops 1-month formulation of goserelin for hormone-sensitive prostate cancer

FDA issues complete response letter rejecting approval of Gilead's NDA for aztreonam lysine

Sucampo presents results from Japanese phase IIb Amitiza trial

Erbitux launched in Japan for the treatment of colorectal cancer

Recent Theravance and Argenta patents describe new treatments for respiratory disorders

FDA grants orphan drug status for patented stem cells in bone marrow transplant

Cyclacel revises operating plan to concentrate resources on advancement of sapacitabine

Sinovac initiates clinical trials in Ukraine of Healive inactivated hepatitis A vaccine

Cleveland BioLabs awarded USD 13.3 million contract for Protectan CBLB-502

Sciele reports results from two phase III studies of glycopyrrolate for pediatric patients

Three Rivers obtains commercial rights in all markets except Japan to Amgen's Infergen

Novel therapeutic agents for cardiovascular disorders covered in recent patents

Eisai describes new treatment options for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...